We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Enhanced Protein Tomography™ Method for Rapid Epitope Determination
Product News

Enhanced Protein Tomography™ Method for Rapid Epitope Determination

Enhanced Protein Tomography™ Method for Rapid Epitope Determination
Product News

Enhanced Protein Tomography™ Method for Rapid Epitope Determination


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Enhanced Protein Tomography™ Method for Rapid Epitope Determination"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Sidec has introduced a new version of its Protein Tomography™ technology. The new developments improve the analysis of therapeutic antibodies and drug targets in biological systems, the company says.

Protein Tomography™ uses regularization theory to create a 3D image from a series of 2D electron microscope images. The enhanced Protein Tomography™ method is developed in order to improve the investigation of the structure and interactions of macromolecules in solution and in cell tissue samples. It does so by speeding up the visualization and analysis steps allowing for rapid identification of binding epitopes and drug target interactions at the molecular level.

“This new technology will improve both the productivity and the applicability of Protein Tomography™ when used to determine e.g. epitopes and will complement existing methods for a better IP strategy and product positioning in the biopharmaceutical industry” Says Anders Aberg CSO at Sidec.

Advertisement